Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
E6005 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Drug: 0.2% E6005 ointment | EXPERIMENTAL | - |
| Drug: 0.0% E6005 ointment (vehicle) | PLACEBO_COMPARATOR | - |
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| E6005 | DRUG | 0.0% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1. |
| E6005 ointment (vehicle) | DRUG | 0.2% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1. |
| Placebo | DRUG | Matching placebo for each step |
Inclusion Criteria * Adults of both genders aged 20 to 64 years at the time when the written informed consent is obtained. * Outpatients diagnosed with atopic dermatitis. Exclusion Criteria * Patients with a present illness of Kaposi's varicelliform eruption, scabies, molluscum contagiosum, impet...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 11 | PHASE3 | Abrocitinib |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab, Corticosteroid |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof, 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Sunshine Biopharma Incorporated | SBFM | 3 | PHASE3 | 611, corticosteroid |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
E6005 is an investigational small molecule being developed for the treatment of atopic dermatitis, a form of eczema. It is currently in clinical development and has not been approved by regulatory authorities. Studies have been conducted in Japanese patients with the condition.
E6005 is being developed by Organon & Co., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol OGN. The drug is in Phase 2 clinical development for atopic dermatitis.
E6005 is in Phase 2 clinical development for atopic dermatitis. It is an investigational drug, meaning it has not yet been approved for commercial use. Two clinical trials have been completed, including a Phase 1 and a Phase 2 study.
E6005 has been studied in two completed clinical trials in Japan. The first, NCT01179880, was a Phase 1 study in 40 male patients with atopic dermatitis. The second, NCT01461941, was a Phase 2 study in 78 patients with atopic dermatitis.
Yes, E6005 has been evaluated in placebo-controlled clinical trials. The Phase 2 study (NCT01461941) used a placebo control group to assess the drug's effects in patients with atopic dermatitis. The trials were randomized but not double-blind.